What is new in therapy?

British Journal of Dermatology

Volumn 145, Issue 5, 2001, Pages 691-695

  Ormerod, A D ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ASCOMYCIN; BCG VACCINE; BETAMETHASONE; CAPSAICIN; CD11 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN; CYTOKINE; EFLORNITHINE; FINASTERIDE; HU 1124; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIAROZOLE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONTELUKAST; NALTREXONE; PIMECROLIMUS; PROBIOTIC AGENT; TACROLIMUS; TERBINAFINE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CLINICAL TRIAL; DRUG POTENCY; ECZEMA; HAIR DISEASE; HUMAN; KAPOSI SARCOMA; LACTOBACILLUS RHAMNOSUS; LENTIGO; MALASSEZIA; MELANOMA; MICROSPORUM AUDOUINII; MYCOSIS; MYCOSIS FUNGOIDES; NONHUMAN; ONYCHOMYCOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURIGO; PRURITUS; PSORIASIS; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN CARCINOMA; TINEA CAPITIS; TRICHOPHYTON; ULTRAVIOLET A RADIATION;

CLINICAL TRIALS; ECZEMA; HUMANS; PSORIASIS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 0035174593     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04503.x     Document Type: Review

References (67)

1. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study
2. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
3. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
4. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
5. The treatment of psoriasis with IL-10: Rationale and review of the first clinical trials
6. Treatment of psoriasis with oral liarozole: A dose-ranging study
7. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation
8. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks
9. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
10. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
11. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study
12. Topical tacrolimus is effective for facial lesions of psoriasis
13. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
14. First experience of topical SDZ ASM 981 in children with atopic dermatitis
15. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial
16. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial
17. Maternal antigen avoidance during pregnancy for preventing atopic disease in infants of women at high risk
18. Effect of house dust mite avoidance measures in children with atopic dermatitis
19. Topical dinitrochlorobenzene therapy in the treatment of refractory atopic dermatitis: Systemic immunotherapy
20. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis
21. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases
22. Treatment of prurigo nodularis with topical capsaicin
23. Finasteride increases anagen hair in men with androgenetic alopecia
24. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
25. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis
26. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis
27. Once weekly fluconazole is effective in children in the treatment of tinea capitis: A prospective, multicentre study
28. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region
29. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis
30. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial
31. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis
32. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma
33. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: Results of a phase III clinical trial
34. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy
35. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: Randomised double-blind trial
36. Systemic photodynamic therapy is a safe and effective treatment for psoriasis
37. Pulsed-dye laser versus conventional therapy in the treatment of warts: A prospective randomized trial
38. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
39. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
40. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
41. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
42. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial
43. Imiquimod 5% cream in the treatment of Bowen's disease
44. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: Results of phase 1 and 2 trials
45. The state-of-the-art in chemoprevention of skin cancer
46. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study
47. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study
48. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies
49. Photodamage pilot study: A double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel
50. 'High-dose' UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides
51. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
52. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy
53. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma
54. PUVA-cream photochemotherapy for the treatment of localized scleroderma
55. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis
56. The use of tetracyclines for the treatment of sarcoidosis
57. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds
58. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial
59. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris
60. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris
61. Effective treatment of frontal hyperhidrosis with botulinum toxin A
62. Botulinum toxin type A therapy for palmar and digital hyperhidrosis
63. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria
64. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
65. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria
66. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus
67. An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid